Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/2/2025

Contraceptive Compatibility with Tranexamic Acid for Heavy Menstrual Bleeding

  • The Centers for Disease Control and Prevention recommends the copper IUD as a compatible option with tranexamic acid, though it may worsen heavy bleeding itself 1
  • The copper IUD itself can cause heavy menstrual bleeding, which creates a clinical paradox—you may be treating the side effect of the contraceptive method itself, and NSAIDs for 5-7 days during menstruation are the recommended first-line treatment for this condition 1

Alternative Treatment Strategy

  • The American College of Obstetricians and Gynecologists suggests that if the patient requires both contraception and treatment for heavy menstrual bleeding, the levonorgestrel-releasing IUD is the superior choice, reducing menstrual blood loss by 71-95% compared to tranexamic acid's 34-60% reduction, providing highly effective contraception, and treating heavy bleeding more effectively than tranexamic acid 2
  • The use of levonorgestrel-releasing IUD often results in amenorrhea over time, which many patients find beneficial, and eliminates the drug interaction concern with tranexamic acid 2

Clinical Considerations

  • The World Health Organization recommends screening for cardiovascular disease and active thromboembolic disease before initiating tranexamic acid, as these are absolute contraindications 3
  • The FDA recommends using tranexamic acid 3.9-4 g per day for 4-5 days starting from the first day of menstruation, and combining it with non-hormonal contraception only, to minimize the risk of thromboembolic events 2

REFERENCES

2

Treatment of Heavy Menstrual Bleeding [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3

Tranexamic Acid Use in Heavy Menstrual Bleeding with Ocular Migraine History [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026